Royalty Report: Medical, cardiac, Supply – Collection: 286596

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Medical
  • cardiac
  • Supply
  • Surgical
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 286596

License Grant
Licensor hereby grants to Licensee an exclusive, perpetual, sub-licensable license to Licensor’s Intellectual Property, Trade Marks (TM), and all technical knowhow in the Fields of Use including Coronary Artery Bypass Grafting, Peripheral Vascular Bypass grafting and other Vascular Surgeries, to enable it to file for regulatory approvals, CE certification, preclinical and clinical studies, manufacture, distribute, market and commercialize the product in the Territory.

Licensor grants to Licensee exclusive, perpetual, sub-licensable rights to Licensor’s IP, Trade Marks (TM), and all technical knowhow to manufacture, distribute, market and commercialize the product in all countries outside the Territory if in any country outside the Territory that Licensor grants to Licensee and Licensee pays for any or all patent related costs or files for registration or files for regulatory approvals, CE certification, preclinical and clinical studies.

Licensor hereby appoints Licensee as an exclusive Distributor of the Product for the Territory in the Field of Use. As such, Licensee shall have the authority to purchase, market and sell the Product in the Territory in the Field of Use. Licensee may not Actively Promote Sales (e.g. through promotion, advertising, or by establishing branches or distribution depots) outside of the Territory. Furthermore, Licensee may only Actively Promote Product for the Field of Use. Licensee hereby accepts such appointment and agrees to use its best efforts to maximize sales of the Product in the Territory in the Field of Use. Licensee acknowledges that Licensees right to distribute is for the Territory in the Field of Use only.

License Property
Products shall refer to the products listed below:
DuraGraft – Vascular Conduit Solution- For use in Cardiac and Peripheral Bypass Grafting with Arteries and Veins and For Vascular Surgeries. The product DuraGraft is a two-component system. Licensor will produce product component A and B either as bulk product or in separate containers ready for packaging to Licensee. Licensor will assist Licensee at Licensee’s cost, with technology transfer to allow Licensee to complete the manufacturing of the DuraGraft product at its ISO13485 certified site in the Territory or and release the product for commercial use in Licensee territories.  Licensor will transfer all Intellectual Property and technologies to manufacture for the currently marketed liquid and the solid dosage form (powder formulation) that requires final development and scale up, of DuraGraft formulations to enable Licensee to manufacture the products at their manufacturing facilities for supply in the Territory.

A CE Marked Product – Notified Body is BSI, Netherlands

Trademarks shall refer to any trademark used by Licensor in connection with the Product, whether derived from common law use, from registration or from statutory protection against unfair competition, including without limitation those rights to Licensor’s corporate name, other trade names, model names and trademarks, including DURAGRAFT.

Intellectual Property and technologies are to manufacture for the currently marketed liquid and the solid dosage form (powder formulation) that requires final development and scale up, of DuraGraft formulations to enable Licensee to manufacture the products at their manufacturing facilities for supply in the Territory.

Field of Use
Field of Use shall refer to use of the Product to preserve vascular conduits used in bypasses in cardiovascular surgery, peripheral bypass surgery and other vascular surgeries.

DuraGraft is a vascular graft treatment that improves clinical outcomes by reducing the incidence and complications of graft failure.

IPSCIO Record ID: 27346

License Grant
Biograft peripheral vascular graft; Biograft is used to bypass occluded blood vessels and is produced from modified human umbilical veins; for use in lower limb vascular reconstructions when a saphenous vein is not available.

IPSCIO Record ID: 203364

License Grant
Transferee, the founder, desires to acquire the Project from Licensor/Transferor and continue its development.
Licensor transfers to Transferee all right, title and interest in and to all of the intellectual property, designs, ideas and concepts concerning the Project. Transferee understands and agrees that beyond the sketches and preliminary prototypes, there are no fixed assets associated with the Project.
License Property
The property being transferred is a synthetic vascular graft device incorporating a manifold connection to the native artery and a preliminary patent search on the subject has been prepared (the Project).
Field of Use
The artificial graft is for coronary artery bypass surgery.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.